Baseline demographics
| Characteristic . | EBd (n = 77) . | Bd (n = 75) . | Total (n = 152) . |
|---|---|---|---|
| Age | |||
| Mean (range), y | 65 (25-82) | 65 (30-85) | 65 (25-85) |
| Age group, n (%) | |||
| <65 y | 34 (44) | 33 (44) | 67 (44) |
| ≥65 y | 43 (56) | 42 (56) | 85 (56) |
| ≥75 y | 15 (19) | 14 (19) | 29 (19) |
| Male sex, n (%) | 42 (55) | 37 (49) | 79 (52) |
| Race, n (%) | |||
| White | 68 (88) | 65 (87) | 133 (88) |
| Black/African American | 4 (5) | 7 (9) | 11 (7) |
| ECOG PS, n (%) | |||
| 0 | 38 (49) | 46 (61) | 84 (55) |
| 1 | 35 (46) | 23 (31) | 58 (38) |
| 2 | 2 (3) | 6 (8) | 8 (5) |
| Not reported | 2 (3) | 0 | 2 (1) |
| Prior lines of therapy, n (%) | |||
| 1 | 50 (65) | 51 (68) | 101 (66) |
| 2 or 3 | 27 (35) | 24 (32) | 51 (34) |
| Months since diagnosis | |||
| Median (range) | 45 (9-296) | 44 (8-285) | 45 (8-296) |
| Prior PI use per IVRS, n (%) | |||
| Yes | 38 (49) | 37 (49) | 75 (49) |
| No | 39 (51) | 38 (51) | 77 (51) |
| ISS stage, n (%) | |||
| I | 26 (34) | 19 (25) | 45 (30) |
| II | 23 (30) | 20 (27) | 43 (28) |
| III | 11 (14) | 16 (21) | 27 (18) |
| Not reported | 17 (22) | 20 (27) | 37 (24) |
| Risk category, n (%) | |||
| High* | 0 | 5 (7) | 5 (3) |
| Low† | 0 | 3 (4) | 3 (2) |
| Standard‡ | 36 (47) | 25 (33) | 61 (40) |
| Not evaluable | 41 (53) | 42 (56) | 83 (55) |
| Characteristic . | EBd (n = 77) . | Bd (n = 75) . | Total (n = 152) . |
|---|---|---|---|
| Age | |||
| Mean (range), y | 65 (25-82) | 65 (30-85) | 65 (25-85) |
| Age group, n (%) | |||
| <65 y | 34 (44) | 33 (44) | 67 (44) |
| ≥65 y | 43 (56) | 42 (56) | 85 (56) |
| ≥75 y | 15 (19) | 14 (19) | 29 (19) |
| Male sex, n (%) | 42 (55) | 37 (49) | 79 (52) |
| Race, n (%) | |||
| White | 68 (88) | 65 (87) | 133 (88) |
| Black/African American | 4 (5) | 7 (9) | 11 (7) |
| ECOG PS, n (%) | |||
| 0 | 38 (49) | 46 (61) | 84 (55) |
| 1 | 35 (46) | 23 (31) | 58 (38) |
| 2 | 2 (3) | 6 (8) | 8 (5) |
| Not reported | 2 (3) | 0 | 2 (1) |
| Prior lines of therapy, n (%) | |||
| 1 | 50 (65) | 51 (68) | 101 (66) |
| 2 or 3 | 27 (35) | 24 (32) | 51 (34) |
| Months since diagnosis | |||
| Median (range) | 45 (9-296) | 44 (8-285) | 45 (8-296) |
| Prior PI use per IVRS, n (%) | |||
| Yes | 38 (49) | 37 (49) | 75 (49) |
| No | 39 (51) | 38 (51) | 77 (51) |
| ISS stage, n (%) | |||
| I | 26 (34) | 19 (25) | 45 (30) |
| II | 23 (30) | 20 (27) | 43 (28) |
| III | 11 (14) | 16 (21) | 27 (18) |
| Not reported | 17 (22) | 20 (27) | 37 (24) |
| Risk category, n (%) | |||
| High* | 0 | 5 (7) | 5 (3) |
| Low† | 0 | 3 (4) | 3 (2) |
| Standard‡ | 36 (47) | 25 (33) | 61 (40) |
| Not evaluable | 41 (53) | 42 (56) | 83 (55) |